Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Three new Bulk Drug...

    Three new Bulk Drug Parks to receive 200 cr each from Govt

    Written by savita thakur thakur Published On 2016-04-30T12:03:48+05:30  |  Updated On 30 April 2016 12:03 PM IST
    Three new Bulk Drug Parks to receive 200 cr each from Govt

    New Delhi : Government is looking at the financial viability for providing Rs 200 crore each to three new bulk drug manufacturing parks in order to create common minimum facilities, Parliament was informed.


    In 2013, government had constituted a high level committee headed by V M Katoch to study the whole issue of active pharmaceutical ingredients (APIs) of critical importance.


    "The committee has since submitted its recommendations. After examining the recommendations, government is now looking into the financial viability of supporting the proposal for providing assistance for common minimum facilities for three greenfield bulk drugs/API parks to the extent of Rs 200 crore each," Minister of State for Chemicals and Fertilisers Hansraj Gangaram Ahir said in a written reply to the Rajya Sabha.


    However, the minister did not mention which three new bulk drug manufacturing parks would be receiving the assistance.


    The panel was also given the mandate to work out a package of interventions/concessions required to build domestic production capabilities and examine the cost implications.


    It has suggested setting up of mega parks to manufacture APIs with common facilities like testing, power and effluent treatment plants. It has also suggested establishing common utilities and services such as storage, testing laboratories, IPR management, designing and guest house/accommodation maintained by a separate special purpose vehicle (SPV).


    The committee has also recommended fiscal and financial benefits to promote the sector.


    The government is also working in association with Ministry of Environment, Forests and Climate Change and Ministry of Commerce & Industry to sort out issues relating to the difficulties being faced by the bulk drug manufacturers relating to environmental issues, Ahir said.


    Bulk drugs are used as raw materials by the pharma industry. India meets about 80 per cent of its demand of bulk drugs through import from China.

    Active Pharmaceutical IngredientAPIBulk drugHansraj Gangaram AhirIPRspecial purpose vehicleSPVV M Katoch
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok